Every Form 4 that Impact BioMedical, Inc. (IBO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IBO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IBO filings page.
DSS, Inc., identified as a ten percent owner of Impact Biomedical Inc. (IBO), reported direct sales totaling 906 common shares: 723 shares on September 22, 2026, at $0.5500 per share; 27 shares on September 23 at $6.9500; and 156 shares on September 24 at $7.0587. No Rule 10b5-1 plan is reported.
IMPACT BIOMEDICAL INC. Chief Financial Officer Todd D. Macko reported open-market sales of 45,000 shares of Common Stock. The transactions occurred on March 25 and March 27, 2026 at prices around $0.60 per share. After these sales, he directly holds 155,122 shares of Common Stock.
IMPACT BIOMEDICAL INC. director Jason Grady reported an open-market sale of 50,000 shares of common stock at an average price of $0.6501 per share. After the transaction, he directly holds 250,182 common shares, indicating he retains a substantial ongoing equity stake in the company.
Impact Biomedical Inc. reported insider share sales by a reporting entity that is a wholly owned subsidiary of DSS, Inc. The insider sold 115,600 shares of common stock on 05/22/2025 at an average price of $0.5491 per share and 45,400 shares on 05/27/2025 at an average price of $0.5403 per share, both coded as sales. After these transactions, the reporting person beneficially owns 545,024 shares of Impact Biomedical common stock, held directly.
The filing is an amendment that corrects a previous error in the number of Impact Biomedical shares that DSS, Inc. beneficially owns. The corrected figure includes 545,024 shares received in connection with the Celios asset sale.